NCT02985996View on ClinicalTrials.gov

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 6, 2017

Primary Completion Date

November 29, 2017

Study Completion Date

November 29, 2017

Conditions
HIV Infections
Interventions
DRUG

Truvada

Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.

DRUG

Genvoya

Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.

Trial Locations (1)

30322

Emory University, Atlanta

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

lead

Emory University

OTHER

NCT02985996 - Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities | Biotech Hunter | Biotech Hunter